Compare Citius Pharmaceuticals Inc (CTXR) vs Vanguard Tax Managed Fund FTSE Developed Markets ETF (VEA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Vanguard Tax Managed Fund FTSE Developed Markets ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.62M), while Vanguard Tax Managed Fund FTSE Developed Markets ETF trades at $70.45 (market cap $323.80B). The key difference: Vanguard Tax Managed Fund FTSE Developed Markets ETF is far larger — about 23773.9× Citius Pharmaceuticals Inc's market cap, and Vanguard Tax Managed Fund FTSE Developed Markets ETF is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and Vanguard Tax Managed Fund FTSE Developed Markets ETF for 131 Days on average.
| CTXR | VEA | |
|---|---|---|
Market Cap | $13.62M | $323.80B |
Volume | 132,438 | 17,001,112 |
Sector | Health | — |
52-Week High | $1.82 | $73.79 |
52-Week Low | $0.48 | $58.90 |
Typical Hold Time | 16 Days | 131 Days |
Enterprise Value | $3.79M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
Vanguard FTSE Developed Markets ETF (VEA) trades at $70.26, down 1.2% today, with a bearish technical signal from moving averages. The ETF offers exposure to developed markets outside the U.S. with a low 0.03% expense ratio and a recent dividend declared for September 2026. Recent news highlights its cost advantage over peers and mixed institutional activity, with some firms increasing stakes while others reduced positions.
VEA provides diversified international exposure at minimal cost, but near-term technical weakness and reliance on global economic stability pose risks. The fund's appeal lies in its efficiency and yield, yet investors face currency and geopolitical uncertainties inherent in non-U.S. markets. Long-term prospects depend on sustained growth in developed economies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Vanguard Tax Managed Fund FTSE Developed Markets ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Developed All Cap ex US Index, a market-capitalization-weighted index that is made up of approximately 4022 common stocks of large-, mid-, and small-cap companies located in Canada and the major markets of Europe and the Pacific region. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VEA →
